📄 Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk.

Early data from Wuhan, China show that patients with COVID-19 are typically male, aged 40 to 60 years, and about one-third have comorbidities. Moreover, of 138 COVID-19 patients hospitalized in Wuhan and treated in an intensive care unit (ICU), 25% had cardiovascular disease and 58% hypertension; the respective figures for non-ICU-treated COVID-19 patients were 10% and 22% [1]. Based on these early data, a predisposition to acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD) may significantly increase the severity of COVID-19 in susceptible individuals.

keywords 🔗 COVID-19 (1240) 🔗 PCSK9 inhibitors () 🔗 atherosclerosis () 🔗 cardiovascular disease (36) 🔗 coronavirus (5664) 🔗 statins (4) 🔗 intensive care (105)

download 🔖 [BibTeX]